Related by context. All words. (Click for frequent words.) 76 metastatic colorectal cancer 74 advanced NSCLC 73 HER2 positive breast cancer 72 HER2 positive 71 metastatic pancreatic cancer 71 NSCLC 71 ovarian cancer 71 metastatic disease 70 metastatic 70 hormone refractory prostate cancer 69 multiple myeloma 69 colorectal cancer 68 HER2 positive metastatic breast 68 metastatic prostate cancer 67 cell lung cancer 67 gastric cancer 67 metastatic cancer 67 metastatic NSCLC 67 recurrent ovarian cancer 67 renal cell carcinoma 67 metastatic renal cell carcinoma 66 docetaxel 65 trastuzumab 65 metastatic melanoma 65 breast cancer 64 adjuvant therapy 63 metastatic colon cancer 63 metastatic RCC 63 HRPC 63 cetuximab 63 advanced unresectable 63 colon cancer 63 erlotinib 63 recurrent prostate cancer 63 brain metastases 62 hormone receptor positive 62 mRCC 62 sorafenib 62 HER2 + 62 HER2 negative 62 relapsed ovarian cancer 62 capecitabine 62 pancreatic adenocarcinoma 62 gemcitabine 62 castration resistant prostate cancer 62 bevacizumab 61 unresectable 61 sunitinib 61 prostate cancer HRPC 61 soft tissue sarcoma 61 myeloma 60 neoadjuvant chemotherapy 60 prostate cancer 60 gastrointestinal stromal tumor GIST 60 mCRC 60 solid tumors 60 recurrent NSCLC 60 chronic lymphocytic leukemia CLL 60 glioblastoma 60 chemoradiotherapy 60 melanoma 60 Metastatic Breast Cancer 60 Herceptin 60 malignant pleural mesothelioma 60 resistant ovarian cancer 60 localized prostate cancer 60 cisplatin 59 bone metastases 59 eribulin mesylate 59 gemcitabine chemotherapy 59 Sutent 59 Taxotere 59 non squamous NSCLC 59 taxane 59 hepatocellular cancer 59 breast cancers 59 liver cancer 59 chemotherapy regimen 59 pancreatic cancer 59 platinum refractory 59 breast cancer recurrence 59 lapatinib 59 chemotherapy regimens 59 chronic lymphocytic leukemia 59 gastrointestinal stromal tumors 59 prostate cancer CRPC 59 vandetanib 59 Avastin 58 sarcoma 58 HER2 58 refractory multiple myeloma 58 gefitinib 58 Vectibix 58 carcinoma 58 axitinib 58 Herceptin trastuzumab 58 temozolomide 58 diagnosed multiple myeloma 58 ovarian cancers 58 Afinitor 58 hormonal therapy 58 temsirolimus 58 bladder cancer 58 bortezomib 58 operable breast cancer 58 superficial bladder cancer 58 lymphoma CTCL 58 glufosfamide 58 metastatic HER2 positive 58 SCCHN 58 fallopian tube carcinoma 58 breast tumors 58 adjuvant chemotherapy 58 chemotherapy 58 irinotecan 58 CLL 58 heavily pretreated 58 stage IIIB 58 chemoradiation 57 tumor recurrence 57 pemetrexed 57 Xeloda 57 docetaxel chemotherapy 57 lung cancer 57 Tarceva 57 Taxotere R 57 endometrial cancer 57 Torisel 57 pancreatic NET 57 follicular lymphoma 57 IRESSA 57 bevacizumab Avastin 57 hepatocellular carcinoma HCC 57 Hepatocellular Carcinoma HCC 57 Taxotere ® 57 metastatic colorectal 57 tamoxifen 57 invasive breast cancer 57 Lapatinib 57 prostate cancers 57 liver metastases 57 metastatic GIST 57 metastatic gastric 57 squamous cell carcinoma 57 GIST 57 Femara 57 acute myelogenous leukemia AML 57 medullary thyroid cancer 57 YONDELIS 56 lupus nephritis 56 cancer 56 distant metastases 56 neoadjuvant therapy 56 T DM1 56 IV NSCLC 56 metastases 56 metastatic malignant melanoma 56 FOLOTYN 56 biologic therapy 56 Multiple Myeloma 56 IV melanoma 56 Tykerb 56 lymphoma 56 chemotherapeutic agent 56 carboplatin 56 IMGN# 56 metastatic carcinoma 56 gastrointestinal stromal tumors GIST 56 pancreatic neuroendocrine tumors 56 EGFR mutation 56 sorafenib Nexavar ® 56 vinorelbine 56 cancers 56 B CLL 55 tumors 55 refractory ovarian cancer 55 hepatocellular carcinoma 55 hormonal therapies 55 Nexavar 55 Hycamtin 55 TACE 55 colorectal cancers 55 malignant melanoma 55 neoadjuvant treatment 55 eribulin 55 Halaven 55 Amrubicin 55 colorectal cancer CRC 55 nab paclitaxel 55 pertuzumab 55 cytotoxic therapy 55 anthracyclines 55 carcinoid cancer 55 taxane therapy 55 irinotecan chemotherapy 55 idiopathic pulmonary fibrosis IPF 55 neuroendocrine tumors 55 relapsed SCLC 55 malignancies 55 rectal cancer 55 cisplatin chemotherapy 55 anthracycline taxane 55 metastatic HER2 negative 55 metastatic CRPC 55 unresectable locally advanced 55 trabectedin 55 chlorambucil 55 carboplatin paclitaxel 55 severe sepsis 55 pegylated liposomal doxorubicin 55 relapsed refractory multiple myeloma 55 Avastin bevacizumab 55 paclitaxel 55 epithelial ovarian cancer 55 metastatic squamous cell carcinoma 55 standard chemotherapy regimens 55 relapsing remitting multiple sclerosis 55 dasatinib 55 metastatic renal cell 55 prostate cancer mCRPC 55 heavily pretreated patients 55 recurrent metastatic 55 nonsmall cell lung cancer 55 ixabepilone 55 pazopanib 55 stage IIIA 55 leukemia AML 55 sorafenib Nexavar 54 systemic lupus erythematosus 54 Velcade bortezomib 54 refractory CTCL 54 IV metastatic melanoma 54 Taxotere docetaxel 54 Xyotax 54 soft tissue sarcomas 54 adjuvant radiation 54 ABRAXANE 54 disease progression 54 rituximab 54 Neoadjuvant 54 endometriosis 54 abiraterone 54 tamoxifen therapy 54 PROVENGE 54 zoledronic acid 54 cutaneous T cell 54 abiraterone acetate 54 bone metastasis 54 luteinizing hormone releasing 54 ipilimumab 54 cetuximab Erbitux 54 Sunitinib 54 AA amyloidosis 54 DLBCL 54 chronic myeloid leukemia CML 54 cabazitaxel 54 leukemia CLL 54 relapsed refractory 54 adenocarcinoma 54 metastatic cancers 54 TEMODAL 54 systemic lupus erythematosus SLE 54 indolent NHL 54 5 fluorouracil 54 imatinib 54 dacarbazine 54 assessing T DM1 54 Bezielle 54 mCRC patients 54 cytotoxic chemotherapy 54 trastuzumab Herceptin ® 54 docetaxel Taxotere ® 54 clinically localized prostate 54 malignancy 54 HCV infected 54 Erlotinib 54 metastatic lung cancer 54 endocrine therapy 54 differentiated thyroid 54 relapsed multiple myeloma 54 carfilzomib 54 pancreatic cancers 54 colorectal liver metastases 54 TORISEL 54 HNSCC 54 hematological cancers 54 advanced epithelial ovarian 54 pralatrexate 53 sunitinib malate 53 bendamustine 53 bladder cancers 53 aflibercept 53 Irinotecan 53 SHPT 53 OncoVEX GM CSF 53 cell lymphoma CTCL 53 docetaxel Taxotere 53 CRPC 53 distant metastasis 53 anastrozole 53 VIDAZA 53 hematologic malignancies 53 endometrial cancers 53 afatinib 53 Metastatic breast cancer 53 Trastuzumab 53 acute myeloid leukemia 53 metastatic CRC 53 docetaxel Taxotere R 53 metastatic bladder 53 basal cell carcinoma BCC 53 REVLIMID 53 panitumumab 53 carcinoid tumors 53 rheumatoid arthritis RA 53 metastatic kidney 53 Gemcitabine 53 relapsing multiple sclerosis 53 recurrent glioblastoma multiforme 53 advanced HER2 positive 53 iniparib 53 trastuzumab Herceptin 53 epithelial ovarian 53 pomalidomide 53 topotecan 53 letrozole 53 non Hodgkin lymphoma 53 alvespimycin 53 tyrosine kinase inhibitor 53 Cytoxan 53 Cetuximab 53 relapsing MS 53 gastrointestinal cancers 53 ASA# 53 leukemia ALL 53 Erbitux cetuximab 53 Folotyn 53 prostate cancer AIPC 53 chemotherapeutic agents 53 refractory AML 53 monotherapy 53 Erbitux 53 gefitinib Iressa 53 stage IIIB IV 53 decitabine 53 preoperative chemotherapy 53 non squamous 53 phase IIb clinical 53 CR# vcMMAE 53 PCa 53 androgen independent 53 metastatic breast 53 metastatic hormone refractory 53 Amigal 53 BCG refractory 53 EFAPROXYN 53 acute myeloid leukemia AML 53 unresectable liver cancer 53 entinostat 53 refractory metastatic colorectal cancer 53 TYKERB 53 depsipeptide 53 Faslodex 52 HGS ETR1 52 postmenopausal women 52 azacitidine 52 estrogen receptor positive 52 pancreatic carcinoma 52 relapsed CLL 52 ToGA 52 scleroderma 52 multiple myeloma MM 52 VELCADE 52 unresectable stage 52 Bortezomib 52 EGFR expressing 52 ELACYT 52 Nexavar sorafenib 52 Proxinium TM 52 chemotherapy cisplatin 52 breast carcinoma 52 paclitaxel Taxol R 52 EGFR 52 T#I mutation 52 Fludara 52 recurrent ovarian 52 Rituxan rituximab 52 Crohn disease 52 TNFerade 52 tumors GIST 52 Acute Myelogenous Leukemia AML 52 antitumor effect 52 ZACTIMA 52 squamous cell cancer 52 Zolinza 52 5 FU 52 angiogenesis inhibitor 52 neoadjuvant 52 ErbB2 positive 52 peritoneal carcinomatosis 52 Velcade 52 lung tumors 52 cell carcinoma 52 tocilizumab 52 FOLFOX4 52 Metastatic Colorectal Cancer 52 Ceflatonin 52 TRISENOX 52 Pemetrexed 52 fludarabine 52 phenoxodiol 52 sorafenib tablets 52 trastuzumab DM1 52 lupus 52 inoperable pancreatic cancer 52 mycophenolate mofetil 52 FOLFOX 52 tyrosine kinase inhibitors 52 plus dexamethasone 52 Everolimus 52 follicular NHL 52 mTOR inhibitor 52 BCIRG 52 locoregional 52 imatinib therapy 52 Sorafenib 52 chronic ITP patients 52 urothelial bladder cancer 52 fluoropyrimidine 52 CaP 52 GnRH agonists 52 peritoneal cancer 52 adjuvant radiotherapy 52 CANCIDAS 52 standard chemotherapy regimen 52 castrate resistant prostate cancer 52 paclitaxel carboplatin 52 pegylated interferon 52 squamous cell 52 nilotinib 52 biliary tract cancer 52 FOLFIRI 52 EGFR TKI 52 refractory Hodgkin lymphoma 52 epirubicin 52 adalimumab 52 Tarceva erlotinib 52 Cotara 52 neoplasia 52 BRCA mutations 52 opioid induced constipation OIC 52 Fludara ® 51 Chronic Lymphocytic Leukemia 51 HCV infection 51 ERBITUX 51 KRAS mutant tumors 51 Doxil ® 51 gynecologic cancers 51 IIIB NSCLC 51 CMV disease 51 Xeloda capecitabine 51 chronic ITP 51 refractory CLL 51 KRAS status 51 perifosine 51 Jevtana 51 evaluating T DM1 51 panitumumab Vectibix 51 tesetaxel 51 imatinib Gleevec 51 capecitabine Xeloda 51 OPAXIO 51 bevacizumab Avastin ® 51 nasopharyngeal carcinoma 51 bowel cancer 51 refractory PTCL 51 advanced hepatocellular carcinoma 51 investigational compound 51 cetuximab Erbitux R 51 myelodysplastic syndrome MDS 51 CoFactor 51 adecatumumab 51 5-FU/LV 51 pegylated interferon alpha 51 nonsquamous histology 51 infusional 5-FU/LV 51 pegfilgrastim 51 pleural mesothelioma 51 metastatic castrate resistant 51 picoplatin 51 vemurafenib 51 gynecological cancers 51 AP# [003] 51 Acute Myeloid Leukemia 51 Zevalin 51 Adjuvant chemotherapy 51 IV malignant melanoma 51 oral ridaforolimus 51 valopicitabine 51 erlotinib Tarceva ® 51 axillary dissection 51 panobinostat 51 SUTENT 51 cilengitide 51 ovarian carcinoma 51 myelodysplastic syndromes MDS 51 acute promyelocytic leukemia APL 51 Theratope 51 Abraxane 51 colorectal 51 estrogen receptor negative 51 refractory prostate cancer 51 factor receptor EGFR 51 Gleevec 51 hormone LHRH agonist 51 seminoma 51 resectable 51 Platinol 51 metastatic SCCHN 51 gastric cancers 51 advanced SCCHN 51 randomized Phase 51 refractory NSCLC 51 hormone deprivation 51 remission induction 51 relapsed GBM 51 prostate adenocarcinoma 51 aromatase inhibitor 51 carcinomas 51 chronic angina 51 interferon alfa 51 CellCept 51 Li Fraumeni Syndrome 51 DMARD 51 evaluating tivozanib 51 gemcitabine carboplatin 51 psoriasis 51 goserelin 51 paclitaxel chemotherapy 51 doxorubicin 51 Revlimid lenalidomide 51 Targretin 51 chemotherapy docetaxel 51 anticancer therapy 51 Genasense ® 51 KRAS wild 51 recurrent glioblastoma 51 stage IIIb IV 51 imetelstat 51 receptor tyrosine kinase inhibitor 51 paclitaxel Taxol 51 olaparib 51 Pancreatic Cancer 51 Revlimid 51 metastatic castration resistant 51 cervical carcinoma 51 CTCL 51 registrational trial 51 Cloretazine ® 51 tyrosine kinase inhibitors TKIs 51 radiotherapy 51 imatinib resistant 51 chemoradiation therapy 51 situ LCIS 51 Provenge 51 overexpress HER2 51 COPD 51 lobular carcinoma 51 INCB# [001] 51 plus gemcitabine 51 metastatic sarcoma 51 PLX# 51 Cell Lung Cancer 51 TKI therapy 51 cetuximab Erbitux ® 51 dasatinib Sprycel ® 51 gastrointestinal stromal tumor 51 alkylating agents 51 vismodegib 51 mitoxantrone 51 stage IIIb 51 GvHD 51 NSABP 51 recurrent GBM 51 belinostat 51 tumor progression 50 metastatic ovarian cancer 50 Troxatyl 50 symptomatic BPH 50 myelofibrosis 50 metastatic HER 50 anti leukemic 50 MDV# 50 Alimta 50 satraplatin 50 mapatumumab 50 randomized Phase III 50 IMC A# 50 Rituxan 50 Gefitinib 50 Hodgkin lymphoma 50 cutaneous melanoma 50 Carcinoma 50 prostate cancer CaP 50 glioblastoma multiforme GBM 50 grade gliomas 50 dose cytarabine 50 gynecological cancer 50 Yervoy 50 oesophageal cancer 50 GISTs 50 Paclitaxel 50 EBRT 50 peginterferon 50 pegylated interferon alfa 2a 50 antitumor activity 50 Advexin 50 fallopian tube cancers 50 Alemtuzumab 50 chronic myeloid leukemia 50 KRAS mutation 50 HuMax CD4 50 enzastaurin 50 dasatinib Sprycel 50 AVASTIN 50 overactive bladder OAB 50 advanced metastatic renal 50 contralateral breast cancer 50 evaluating ispinesib 50 CALGB # [001] 50 exemestane 50 estrogen receptor ER 50 taxane chemotherapy 50 HER2 positive tumors 50 free survival PFS 50 nonmetastatic 50 postmenopausal osteoporosis 50 trastuzumab DM1 T DM1 50 prostate tumor 50 lenalidomide Revlimid R 50 registrational 50 osteosarcoma 50 chemotherapies 50 ER CHOP 50 elacytarabine 50 anti EGFR antibody 50 tesmilifene 50 T#I [002] 50 oral deforolimus 50 LUX Lung 50 rectal cancers 50 Dacogen 50 Metastatic 50 Breast Cancer 50 Gleevec resistant 50 Gemzar ® 50 DCVax R Brain 50 Docetaxel 50 LY# [003] 50 5FU 50 Ixempra 50 adjuvant 50 Quinamed 50 clinical trials 50 romiplostim 50 esophageal cancer 50 relapsed MM 50 Bevacizumab 50 acute ischemic stroke 50 Hodgkin Lymphoma 50 colorectal cancer liver metastases 50 advanced metastatic prostate 50 EGFR mutations 50 Vandetanib 50 Tavocept 50 non Hodgkin Lymphoma 50 gynecologic cancer 50 clinical trial 50 CHOP chemotherapy 50 Gleevec imatinib 50 biliary cancer 50 HGS# 50 metastatic adenocarcinoma 50 antibody MAb 50 XELOX 50 ELOXATIN 50 relapsing remitting MS 50 minimally symptomatic 50 IL# PE#QQR 50 YERVOY 50 biliary strictures produced 50 Vicinium TM 50 refractory myeloma 50 anthracycline 50 metastatic colorectal carcinoma 50 Acute Myeloid Leukemia AML 50 metastatic malignant 50 XGEVA 50 Nexavar ® 50 Sutent sunitinib 50 IRX 2 50 oxaliplatin 50 velafermin 50 efalizumab 50 lorvotuzumab mertansine 50 taxanes 50 interferon 50 regorafenib 50 cinacalcet 50 Alpharadin 50 Cloretazine 50 alkylating agent 50 5 Fluorouracil 50 Azacitidine 50 Pertuzumab 50 Breast cancer 50 imatinib Gleevec ® 50 TTF Therapy 50 FTY# 50 relapsed leukemia 50 estramustine 50 non resectable 50 BEXXAR 50 RoACTEMRA 50 radiofrequency ablation RFA 50 unresectable Stage III 50 Aflibercept 50 ZEVALIN 50 Tamoxifen 50 Metastatic Prostate Cancer 50 refractory APL 50 rheumatoid arthritis 50 oral clodronate 50 cancer mCRC 50 IgG1 monoclonal antibody 50 custirsen 50 non metastatic osteosarcoma 50 chemotherapeutic regimen 50 TREANDA 50 Aplidin 50 fluorouracil 50 pegylated liposomal doxorubicin PLD 50 LHRH receptor positive 50 tumor shrinkage 50 serous ovarian cancer 49 ZOLINZA 49 Xgeva 49 Xcytrin 49 ACTEMRA TM 49 BRAF V# mutation 49 invasive carcinoma 49 hormone therapy 49 ALCL 49 relapsed 49 Imatinib 49 KRAS mutations occur 49 Cisplatin 49 CYT# potent vascular disrupting 49 Friedreich Ataxia 49 interferon beta 1a 49 FOLFOX6 49 radiation therapy 49 virologic failure 49 leucovorin 49 endometrial hyperplasia 49 Arranon 49 liposomal doxorubicin 49 Carboplatin 49 Degarelix 49 invasive ductal carcinoma 49 Her2 49 BAY #-# 49 entecavir 49 EGFR expressing mCRC 49 BRAF mutation 49 refractory colorectal cancer 49 palifosfamide 49 Folfox 49 tanespimycin 49 diagnosed GBM 49 Lung cancer 49 medically inoperable 49 breast carcinomas 49 Selective Internal 49 anti TNF 49 chronic HCV 49 elagolix 49 metastatic HRPC 49 APTIVUS r 49 prostate lung 49 prostate carcinoma 49 methylnaltrexone 49 Renal Cell Carcinoma RCC 49 prostate cancer PCa 49 lung metastases 49 Satraplatin 49 recurrent malignant glioma 49 HGS ETR2 49 EpCAM 49 antiplatelet therapy 49 invasive bladder 49 Hodgkin lymphoma NHL 49 Phase 2b study 49 capecitabine Xeloda R 49 zalutumumab 49 chemo radiotherapy 49 EGFr 49 cisplatin resistant 49 Ophena TM 49 Rituximab 49 Navelbine ® 49 androgen deprivation therapy 49 Talabostat 49 node metastases 49 MYDICAR ® 49 lapatinib Tykerb 49 Allovectin 7 49 Certican 49 Ozarelix 49 CTA# Injection 49 HERCEPTIN 49 letrozole Femara 49 androgen deprivation 49 Non Hodgkin Lymphoma 49 micrometastases 49 chronic HCV infection 49 ganetespib 49 evaluating Xcytrin 49 CML CP 49 lung cancers 49 hepatitis C genotype 49 mutated KRAS gene 49 antiviral therapy 49 refractory metastatic 49 cabozantinib 49 severe psoriasis 49 Insegia 49 Xelox 49 figitumumab 49 dexpramipexole 49 Idiopathic Pulmonary Fibrosis 49 postoperative chemotherapy 49 ThermoDox 49 Tamibarotene 49 hormone refractory metastatic prostate 49 NCCTG 49 EGFR inhibitors 49 Mimpara 49 Gemzar 49 everolimus 49 PSADT 49 Ovarian Cancer 49 Natalizumab 49 Phenoptin 49 peginterferon alfa 2a 49 Annamycin 49 Glufosfamide 49 lamivudine 49 Vidaza 49 trastuzumab emtansine T DM1 49 ADVEXIN 49 HER2 receptor 49 concurrent chemoradiation 49 Imprime PGG 49 ovarian lung 49 Mylotarg 49 amrubicin 49 colorectal tumors 49 cetrorelix 49 cediranib 49 pain palliation 49 neuroendocrine cancers 49 histologically confirmed 49 chronic myelogenous leukemia CML 49 chronic hepatitis B 49 visilizumab 49 unresectable tumors 49 Advanced Renal Cell 49 clofarabine 49 nucleoside analogue 49 interferon alfa 2a 49 ALIMTA 49 metformin 49 pulmonary arterial hypertension PAH 49 external beam radiotherapy 49 autoantibody positive 49 PROSTVAC ® 49 daclizumab 49 fibromyalgia syndrome 49 ofatumumab 49 liver fibrosis 49 Yondelis 49 EndoTAGTM 1 49 obatoclax 49 xenograft models 49 aromatase inhibitors 49 dirucotide 49 microwave hyperthermia 49 rituximab Rituxan 49 severe oral mucositis 49 recurrent colorectal cancer 49 idarubicin 49 hormone refractory 49 XYOTAX 49 Bexxar 49 recurrent glioma 49 acute leukemias 49 anti angiogenic therapy 49 metastatic relapsed 49 placebo controlled clinical 49 paclitaxel poliglumex 49 trastuzumab emtansine 49 Navelbine 49 eltrombopag 48 Lung Cancer 48 diabetic nephropathy 48 immunosuppressant 48 grade glioma 48 bipolar depression 48 Pirfenidone 48 NeuroStar TMS Therapy 48 Ceplene/IL-2 48 invasive candidiasis 48 doxorubicin HCl liposome injection 48 metastatic pancreatic 48 relapsed Hodgkin lymphoma 48 lenalidomide 48 BRCA deficient 48 radiochemotherapy 48 menopausal symptoms 48 nimotuzumab 48 HuMax EGFr 48 huC# DM4 48 TAXOTERE R 48 NEUVENGE 48 myelodysplastic syndromes 48 CIPN 48 colon cancers 48 oral chemotherapeutic agent 48 lintuzumab 48 diagnosed glioblastoma multiforme 48 primary peritoneal 48 Glioblastoma Multiforme 48 epithelial tumors 48 cytarabine 48 Acute Myeloid Leukaemia AML 48 ENMD 48 FSAD 48 HER2 positive cancers 48 TYZEKA 48 talactoferrin 48 PSMA ADC 48 colorectal carcinoma 48 plus prednisone 48 HBeAg negative 48 HCV 48 Lymphoma 48 radiation chemoradiation 48 pCR 48 Cetuximab Erbitux 48 squamous histology 48 Hodgkin lymphoma HL 48 forodesine 48 prostate tumors 48 Dasatinib 48 nonsquamous 48 FASLODEX 48 GnRH agonist 48 post menopausal osteoporosis 48 ozarelix 48 cintredekin besudotox 48 ADXS# 48 Ovarian cancer 48 invasive lobular carcinoma 48 Mantle Cell Lymphoma 48 iniparib BSI 48 Pixantrone 48 HER2 overexpression 48 sipuleucel T 48 Betaferon ® 48 RSR# 48 lymphomas 48 EOquin 48 daunorubicin 48 pediatric malignancies 48 transitional cell carcinoma 48 REVLIMID ® 48 PARP inhibitors 48 lumiliximab 48 raltegravir 48 hormone receptor negative 48 natalizumab 48 Neulasta ® 48 ImClone Erbitux 48 Kit CD# positive 48 PXD# 48 trastuzumab Herceptin R 48 Zarnestra 48 Dacogen injection